# MabPlex opens new manufacturing facility in Yantai, China

MabPlex International inaugurated a new Phase III and commercial manufacturing facility in Yantai, Shandong, China. The facility adds 400,000 ft² of cGMP space with six cell culture suites and four purification suites.

- Type: New facility
- Announced: 2018-09-06
- Where: Yantai, Shandong, China
- Starts operating: 6 Sep 2018
- Status: completed
- Capacity: 400,000 ft² cGMP; up to 24,000 L bioreactor capacity
- Products: monoclonal antibodies, antibody-drug conjugates
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [MabPlex International](https://endata.com/companies/32239.md)

## Sources

- [adcreview.com](https://www.adcreview.com/news/mabplex-opens-new-phase-iii-and-commercial-manufacturing-facility/), 2018-12-13: "With a growing number of novel and increasingly complex drug constructs in early development pipelines and new targeted therapies, such as ADCs, in late stage development and moving to commercialization, there is"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.